Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
Jonathan E Rosenberg, Peter H O'Donnell, Arjun V Balar, Bradley A McGregor, Elisabeth I Heath, Evan Y Yu, Matthew D Galsky, Noah M Hahn, Elaina M Gartner, Juan M Pinelli, Shang-Ying Liang, Amal Melhem-Bertrandt, Daniel P Petrylak, Jonathan E Rosenberg, Peter H O'Donnell, Arjun V Balar, Bradley A McGregor, Elisabeth I Heath, Evan Y Yu, Matthew D Galsky, Noah M Hahn, Elaina M Gartner, Juan M Pinelli, Shang-Ying Liang, Amal Melhem-Bertrandt, Daniel P Petrylak
Abstract
Purpose: Locally advanced or metastatic urothelial carcinoma is an incurable disease with limited treatment options, especially for patients who were previously treated with platinum and anti-programmed death 1 or anti-programmed death ligand 1 (PD-1/L1) therapy. Enfortumab vedotin is an antibody-drug conjugate that targets Nectin-4, which is highly expressed in urothelial carcinoma.
Methods: EV-201 is a global, phase II, single-arm study of enfortumab vedotin 1.25 mg/kg (intravenously on days 1, 8, and 15 of every 28-day cycle) in patients with locally advanced or metastatic urothelial carcinoma who were previously treated with platinum chemotherapy and anti-PD-1/L1 therapy. The primary end point was objective response rate per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by blinded independent central review. Key secondary end points were duration of response, progression-free survival, overall survival, safety, and tolerability.
Results: Enfortumab vedotin was administered to 125 patients with metastatic urothelial carcinoma. Median follow-up was 10.2 months (range, 0.5 to 16.5 months). Confirmed objective response rate was 44% (95% CI, 35.1% to 53.2%), including 12% complete responses. Similar responses were observed in prespecified subgroups, such as those patients with liver metastases and those with no response to prior anti-PD-1/L1 therapy. Median duration of response was 7.6 months (range, 0.95 to 11.30+ months). The most common treatment-related adverse events were fatigue (50%), any peripheral neuropathy (50%), alopecia (49%), any rash (48%), decreased appetite (44%), and dysgeusia (40%). No single treatment-related adverse events grade 3 or greater occurred in 10% or more of patients.
Conclusion: Enfortumab vedotin demonstrated a clinically meaningful response rate with a manageable and tolerable safety profile in patients with locally advanced or metastatic urothelial carcinoma who were previously treated with platinum and anti-PD-1/L1 therapies.
Trial registration: ClinicalTrials.gov NCT03219333.
Figures
References
- National Cancer Institute . SEER Cancer Stat Facts: Bladder Cancer. Bethesda, MD: National Cancer Institute; 2019.
- von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068–3077.
- De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30:191–199.
- Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol. 2012;30:1107–1113.
- Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376:1015–1026.
- Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): A multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391:748–757.
- National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Bladder cancer (version .2.2019)
- Challita-Eid PM, Satpayev D, Yang P, et al. Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res. 2016;76:3003–3013.
- Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21:778–784. [Erratum: Nat Biotechnol 21:941, 2003]
- Mandai K, Rikitake Y, Mori M, et al. Nectins and nectin-like molecules in development and disease. Curr Top Dev Biol. 2015;112:197–231.
- Takai Y, Ikeda W, Ogita H, et al. The immunoglobulin-like cell adhesion molecule nectin and its associated protein afadin. Annu Rev Cell Dev Biol. 2008;24:309–342.
- Takai Y, Miyoshi J, Ikeda W, et al. Nectins and nectin-like molecules: Roles in contact inhibition of cell movement and proliferation. Nat Rev Mol Cell Biol. 2008;9:603–615.
- Zhang Y, Zhang J, Shen Q, et al. High expression of nectin-4 is associated with unfavorable prognosis in gastric cancer. Oncol Lett. 2018;15:8789–8795.
- Lattanzio R, Ghasemi R, Brancati F, et al. Membranous nectin-4 expression is a risk factor for distant relapse of T1-T2, N0 luminal-A early breast cancer. Oncogenesis. 2014;3:e118.
- Takano A, Ishikawa N, Nishino R, et al. Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res. 2009;69:6694–6703.
- Pavlova NN, Pallasch C, Elia AE, et al. A role for PVRL4-driven cell-cell interactions in tumorigenesis. eLife. 2013;2:e00358.
- Rosenberg JE, Sridhar SS, Zhang J, et al. Mature results from EV-101: A phase I study of enfortumab vedotin in patients with metastatic urothelial cancer (mUC) J Clin Oncol. 2019;37(abstr 377)
- Rosenberg JE, Heath E, Perez R, et al. Interim analysis of a phase I dose escalation trial of ASG-22CE (ASG-22ME; enfortumab vedotin), an antibody drug conjugate (ADC), in patients (Pts) with metastatic urothelial cancer (mUC) Ann Oncol. 2016;27(abstr 788P)
- Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumours: Revised RECIST guideline (version 1.1) Eur J Cancer. 2009;45:228–247.
- Vaughn DJ, Broome CM, Hussain M, et al. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol. 2002;20:937–940.
- Bellmunt J, Choueiri TK, Fougeray R, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol. 2010;28:1850–1855.
- Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26:404–413.
- Drakaki A, Kirby CJ, Van der Heijden MS, et al. Docetaxel with or without ramucirumab after immune checkpoint inhibition in platinum-refractory metastatic urothelial carcinoma (mUC): Prespecified subgroup analysis from the phase 3 RANGE trial. J Clin Oncol. 2018;36(abstr 434)
- Masters JC, Nickens DJ, Xuan D, et al. Clinical toxicity of antibody drug conjugates: A meta-analysis of payloads. Invest New Drugs. 2018;36:121–135.
Source: PubMed